Equities

Livewire Ergogenics Inc

LVVV:PKC

Livewire Ergogenics Inc

Actions
  • Price (USD)0.0018
  • Today's Change0.00 / 0.00%
  • Shares traded111.11k
  • 1 Year change-62.50%
  • Beta0.9297
Data delayed at least 15 minutes, as of May 30 2024 14:37 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Livewire Ergogenics, Inc. operates in the cannabis-related health and wellness industry. The Company is focused on acquiring, leasing, managing, and licensing special-purpose real estate properties conducive to discovering and developing high-end organic-style cannabinoid specialty products in California for medicinal and recreational use. The Company is establishing, managing, and licensing a vertically integrated Estate Grown Weedery business model to cultivate and sell high-quality handcrafted cannabis products following organic growing guidelines similar to the winery models surrounding Estrella Ranch. Its projects include Estrella Ranch Project, Makana Ola Farms, and SloGrow. The Makana Ola Farms project is a 40-acre parcel with a 9,900 square foot cultivation area located in the heart of Humboldt County in Northern California. It has developed the Estrella Ranch location in Paso Robles, California, into the central hub for all the Company's operations.

  • Revenue in USD (TTM)67.98k
  • Net income in USD-1.09m
  • Incorporated2007
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Resonate Blends Inc101.41k-4.72m3.13m6.00------30.82-0.0537-0.05370.0012-0.00070.0328-------152.56-680.29-----34.87-78.88-4,657.83-12,895.26---0.74131.02---66.73-56.57-316.63------
Seelos Therapeutics Inc1.97m-27.12m3.13m10.00------1.59-44.59-44.592.16-17.360.1449--2.24131,600.00-198.99-180.05---386.76-----1,373.61-9,612.88------------48.48------
Revelation Biosciences Inc0.00-8.96m3.15m9.00--0.3327-----32.09-32.090.005.800.00----0.00-54.61---91.95--------------0.00------98.89------
Sonoma Pharmaceuticals Inc12.31m-5.08m3.19m9.00--0.4186--0.2595-0.9608-0.96081.950.4890.86252.584.761,367,778.00-35.56-37.52-47.14-51.3539.1740.17-41.23-37.123.11--0.0065--5.10-4.44-1.28--7.54--
Aditxt Inc506.45k-41.45m3.20m47.00--0.322--6.31-109.80-109.800.74885.960.02840.92961.3410,775.53-231.82-192.78-658.00-321.59-27.22---8,149.75-7,208.650.0562-3.420.3915---30.90---18.11------
Avenue Therapeutics Inc0.00-7.18m3.24m3.00--0.7159-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Optimus Healthcare Services Inc1.27m-7.79m3.32m17.00------2.62-0.1948-0.19480.0317-0.12910.2595--2.1674,453.53-159.79---2,228.37--77.90---615.77--0.1525-15.4121.18--------------
Livewire Ergogenics Inc67.98k-1.09m3.35m1.00------49.25-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Manuka Inc671.00k-1.14m3.36m4.00------5.01-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
Gold River Productions Inc.-100.00bn-100.00bn3.37m1.00k--5.19----------0.0005----------------------------0.00-------100.11------
Eiger Biopharmaceuticals Inc15.77m-74.96m3.41m25.00------0.2159-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
Bio Path Holdings Inc0.00-13.96m3.41m10.00---------27.39-27.390.00-3.480.00----0.00-216.97-70.80-390.65-76.87---------------------15.94------
Altamira Therapeutics Ltd116.94k-8.06m3.43m10.00--0.3157--29.31-31.28-26.400.2384.850.015134.0532.3011,694.20-103.88-73.80-6,364.67-123.19-87.90---6,892.99--1.38-4.360.0152------61.02------
TRACON Pharmaceuticals Inc12.15m1.75m3.43m17.001.97--1.950.28240.65090.65096.27-0.66181.37----714,411.8019.78-79.42---177.85----14.39-813.81---0.4613------32.0587.68------
60 Degrees Pharmaceuticals Inc378.20k-1.07m3.55m2.00------9.37-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Clearmind Medicine Inc0.00-8.09m3.58m----0.7104-----30.92-30.920.001.590.00-------109.55-218.20-180.61-488.96-----------2.900.0184-------25.03------
Data as of May 30 2024. Currency figures normalised to Livewire Ergogenics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.